Pre-made Lupartumab benchmark antibody ( Whole mAb ADC, anti-LYPD3 therapeutic antibody, Anti-C4.4A Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Lupartumab biosimilar, Whole mAb ADC, Anti-LYPD3 Antibody: Anti-C4.4A therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-329-1mg	1mg	Inquiry
GMP-Bios-ab-329-10mg	10mg	Inquiry
GMP-Bios-ab-329-100mg	100mg	Inquiry
GMP-Bios-ab-329-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Lupartumab biosimilar, Whole mAb ADC, Anti-LYPD3 Antibody: Anti-C4.4A therapeutic antibody
INN Name	Lupartumab
Target	LYPD3
Format	Whole mAb ADC
Derivation	Human
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Lambda
Highest_Clin_Trial (Jan '20)	Phase-I
Est. Status	Active
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2016
Year Recommended	2017
Companies	Bayer HealthCare
Conditions Approved	na
Conditions Active	Solid tumours
Conditions Discontinued	na
Development Tech	na